New Boron Compounds Show Promise Against Treatment-Resistant Cancers | BNCT Breakthrough

Researchers at the Institute of Science Tokyo have developed a new class of boron compounds, termed GluBs, that demonstrate the potential to reach previously tricky-to-treat cancers. These agents offer a novel approach to cancer therapy by entering tumor cells through a different pathway than conventional drugs, potentially expanding treatment options for aggressive cancers like glioblastoma and triple-negative breast cancer. Medical Xpress reported on this development earlier today, highlighting the promise of GluBs in overcoming limitations of existing boron neutron capture therapy (BNCT).

Expanding the Reach of Boron Neutron Capture Therapy

Boron neutron capture therapy (BNCT) is a non-invasive radiotherapy technique that relies on delivering a sufficient amount of boron-10 directly into tumor cells. When exposed to low-energy neutrons, the boron-10 undergoes a nuclear reaction, releasing high-energy particles that selectively destroy the cancer cells while minimizing damage to surrounding healthy tissue. The effectiveness of BNCT hinges on the efficient delivery of boron-10 to the tumor. Currently, the most widely used boron carrier is L-4-boronophenylalanine (BPA). However, BPA’s reliance on the L-type amino acid transporter 1 (LAT1) for tumor entry presents a challenge, as tumors with low LAT1 expression often exhibit poor responses to BNCT. This leaves a significant patient population without effective treatment options.

Targeting ASCT2: A New Avenue for Boron Delivery

To address this limitation, the research team, led by Professor Hiroyuki Nakamura and Associate Professor Kazuki Miura, developed GluBs – glutamate-mimicking boron carriers. These compounds are designed to enter cancer cells via the alanine-serine-cysteine transporter 2 (ASCT2), a nutrient transporter crucial for the metabolic needs of rapidly proliferating tumors. As detailed in the Journal of Controlled Release, GluBs demonstrate preferential uptake in cancer cells with high ASCT2 expression, even in cases where LAT1 expression is low.

How GluBs Differ from Existing Treatments

The key difference lies in the transport mechanism. BPA primarily utilizes LAT1, which is often downregulated in aggressive cancers, limiting its effectiveness. GluBs, by targeting ASCT2, bypass this limitation and can access tumors that were previously considered untreatable with conventional BNCT. ASCT2 is particularly abundant in cancers like triple-negative breast cancer, melanoma, and glioblastoma – all known for their aggressive nature and limited treatment options.

Laboratory and Animal Study Results

The researchers synthesized three different GluB compounds – GluB-1, GluB-2, and GluB-3 – varying in the length of a chemical linker between the core molecule and the boron atom. Laboratory tests revealed that all three compounds exhibited good water solubility, low cytotoxicity at therapeutic doses, and increased accumulation within tumors expressing high levels of ASCT2. GluB-2 emerged as the most promising candidate, demonstrating the best balance between safety and tumor targeting efficiency.

Further testing in animal models – mice with colon tumors and human glioblastoma cells implanted in the brain – showed that GluB-2 effectively delivered boron to the tumors, achieving concentrations exceeding 21 micrograms of boron-10 per gram of tumor tissue within hours of administration. This level surpasses the therapeutic threshold of 20 micrograms per gram required for effective BNCT. Upon neutron irradiation, tumors treated with GluB-2 exhibited significant suppression in growth compared to those treated with BPA. Importantly, the animals showed stable weight and no signs of significant organ damage, suggesting good tolerability.

Implications for Cancer Treatment and Future Research

This study represents a significant step forward in expanding the applicability of BNCT. By successfully designing boron carriers that target ASCT2, researchers have opened a new therapeutic avenue for patients whose tumors are refractory to BPA-based BNCT. The findings suggest that GluBs could potentially broaden the range of cancers treatable with this non-invasive radiotherapy technique.

However, it’s crucial to acknowledge the limitations of these early findings. The research is currently limited to laboratory and animal studies. Further investigation is needed to confirm the safety and efficacy of GluBs in human clinical trials. The long-term effects of GluB treatment and potential off-target effects also require careful evaluation.

What’s Next: Clinical Trials and Further Development

The research team is now focused on preparing for human clinical trials to assess the safety and efficacy of GluB-2 in cancer patients. These trials will be critical in determining whether the promising results observed in preclinical studies translate to clinical benefit. Researchers will also continue to refine the GluB compounds, optimizing their structure and delivery methods to maximize tumor boron concentration and minimize potential side effects. The Institute of Science Tokyo is actively seeking collaborations to accelerate the development and clinical translation of this innovative cancer therapy.

The development of GluBs underscores the importance of continued research into novel boron carriers for BNCT. As our understanding of tumor biology and transport mechanisms grows, we can expect to witness further advancements in targeted cancer therapies that offer hope for patients with previously untreatable diseases.